Nearly two-thirds of people stop taking weight loss drugs due to side effects and cost
The majority of patients prescribed weight loss drugs for obesity stop taking them because of side effects and cost, according to the...
Nearly two-thirds of people stop taking weight loss drugs due to side effects and cost
No overall cost–benefit after RYGB versus SG among T2DM patients
Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss
Half the global population will be living with overweight and obesity by 2035
Journal Watch 4/01/2023
Annual costs of rising overweight and obesity rates estimated at US$2.2 trillion
No significant difference between costs, mortality and re-admissions between RYGB and SG